Phase 4 Lupus Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years old
• People who have been diagnosed with lupus nephritis (a form of kidney disease linked to lupus) confirmed by a kidney biopsy, classified as class III, IV, III/V, or IV/V under a standard medical classification system
• People whose urine test shows a protein-to-creatinine ratio of at least 0.5 but less than 5.0 g/g, measured from a first morning urine sample
• People whose kidneys are functioning at a level of at least 45 mL/min/1.73 m² as measured by a standard kidney function test (eGFR)
• People who are already receiving, or who will begin receiving by Day 1 of the trial, one of the following medications: belimumab, anifrolumab, or obinutuzumab (those on obinutuzumab must have already received at least two doses before the screening stage)
• People who are willing to take a medication called a mycophenolic acid analog (MPAA), either by continuing a current prescription or starting it by Day 1
• People who are willing to take corticosteroids (such as prednisone or an equivalent), either by continuing a current prescription or starting it by Day 1

Who may not be able to join:

• People who have received any B-cell targeted therapy (other than belimumab or obinutuzumab) within the past year, unless blood tests show their B-cell count is back within the normal range
• People who have taken cyclophosphamide, or certain immune-suppressing medications called calcineurin inhibitors (such as cyclosporine or tacrolimus, but not voclosporin), within the past 3 months
• People who have taken certain other immune-suppressing medications within roughly the past 30 days or longer (depending on how long the medication stays in the body), including TNF-blocking therapies (such as adalimumab, etanercept, or infliximab), certain anti-inflammatory biologics (such as tocilizumab, ustekinumab, or dupilumab), a T-cell targeting medication called abatacept, intravenous immunoglobulin (IVIg), or JAK inhibitor medications such as upadacitinib (confirm with trial site for the full list)
• People who are pregnant, breastfeeding, or planning to become pregnant during the trial

Important: Always verify eligibility with the trial site directly before applying.